Acrivon therapeutics inc ACRV.US Overview Analysis
ACRV AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
ACRV Current Performance
-5.83%
Acrivon therapeutics inc
2.24%
Avg of Sector
0.72%
S&P500
Top 10 High Relevance to ACRV
- GERN Geron corporationValue 4Trend 2Swing Trading 2Whale Interest 2Dividend 1See more
ACRV Profile
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.